GPT and metabolic dysfunction-associated steatotic liver disease: Of note, the De Ritis Ratio (AST/ALT) in the isorhamnetin group was significantly reduced compared to the HFD group, powerfully endorsing isorhamnetin’s efficacy in mitigating NAFLD (Figure 4K).